Cargando…

Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity

Ruthenium compounds have become promising alternatives to platinum drugs by displaying specific activities against different cancers and favourable toxicity and clearance properties. Nonetheless, their molecular targeting and mechanism of action are poorly understood. Here we study two prototypical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adhireksan, Zenita, Davey, Gabriela E., Campomanes, Pablo, Groessl, Michael, Clavel, Catherine M., Yu, Haojie, Nazarov, Alexey A., Yeo, Charmian Hui Fang, Ang, Wee Han, Dröge, Peter, Rothlisberger, Ursula, Dyson, Paul J., Davey, Curt A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Pub. Group 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959212/ https://www.ncbi.nlm.nih.gov/pubmed/24637564 http://dx.doi.org/10.1038/ncomms4462

Ejemplares similares

Allosteric cross-talk in chromatin can mediate drug-drug synergy
por: Adhireksan, Zenita, et al.
Publicado: (2017)

Nucleosome acidic patch-targeting binuclear ruthenium compounds induce aberrant chromatin condensation
por: Davey, Gabriela E., et al.
Publicado: (2017)

Near-atomic resolution structures of interdigitated nucleosome fibres
por: Adhireksan, Zenita, et al.
Publicado: (2020)

p-Cymene Complexes of Ruthenium(II) as Antitumor Agents
por: Pujante-Galián, María Angeles, et al.
Publicado: (2020)

Engineering nucleosomes for generating diverse chromatin assemblies
por: Adhireksan, Zenita, et al.
Publicado: (2021)

Physicochemical Studies and Anticancer Potency of Ruthenium η(6)-p-Cymene Complexes Containing Antibacterial Quinolones
por: Kljun, Jakob, et al.
Publicado: (2011)

Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation
por: Wu, Bin, et al.
Publicado: (2011)

DNA-Binding Capabilities and Anticancer Activities of Ruthenium(II) Cymene Complexes with (Poly)cyclic Aromatic Diamine Ligands
por: Alsaeedi, Mona S., et al.
Publicado: (2020)

Dichlorido(η(6)-p-cymene)(ethoxydiphenylphosphane)ruthenium(II)
por: Knapp, Spring M. M., et al.
Publicado: (2012)

Dichlorido(η(6)-p-cymene)(4-fluoroaniline-κN)ruthenium(II)
por: Sykora, Richard E., et al.
Publicado: (2010)

Anticancer and antimicrobial properties of novel η(6)-p-cymene ruthenium(ii) complexes containing a N,S-type ligand, their structural and theoretical characterization
por: Namiecińska, Ewelina, et al.
Publicado: (2019)

Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies
por: Palermo, Giulia, et al.
Publicado: (2015)

(η(6)-p-Cymene)bis(trichloridostannyl)(triethoxyphosphine-κP)ruthenium(II)
por: Shapovalov, Sergey S., et al.
Publicado: (2009)

Stereochemical control of nucleosome targeting by platinum-intercalator antitumor agents
por: Chua, Eugene Y.D., et al.
Publicado: (2015)

Facile Arene Ligand Exchange in p-Cymene Ruthenium(II) Complexes of Tertiary P-Chiral Ferrocenyl Phosphines
por: Popp, John, et al.
Publicado: (2019)

Tuning the Cytotoxicity of Bis-Phosphino-Amines Ruthenium(II) Para-Cymene Complexes for Clinical Development in Breast Cancer
por: Domínguez-Jurado, Elena, et al.
Publicado: (2021)

Synthesis, Characterization, and Cytotoxicity Studies of N-(4-Methoxybenzyl) Thiosemicarbazone Derivatives and Their Ruthenium(II)-p-cymene Complexes
por: Martínez-Estévez, Mónica, et al.
Publicado: (2022)

Dichlorido(η(6)-p-cymene)[tris(4-methoxyphenyl)phosphane]ruthenium(II)
por: Davis, Wade L., et al.
Publicado: (2021)

NRF2 and Bip Interconnection Mediates Resistance to the Organometallic Ruthenium-Cymene Bisdemethoxycurcumin Complex Cytotoxicity in Colon Cancer Cells
por: Garufi, Alessia, et al.
Publicado: (2023)

Crystal structure of [3-amino-2-(phenyldiazenyl)pyridine]chlorido(η(6)-p-cymene)ruthenium(II) chloride
por: Hansongnern, Kanidtha, et al.
Publicado: (2015)

Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters
por: Nazarov, Alexey A., et al.
Publicado: (2013)

μ-Pyrazine-2,5-dicarboxylato-bis[chlorido(η(6)-p-cymene)ruthenium(II)] tert-butanol disolvate
por: Sanchez Ballester, Noelia M., et al.
Publicado: (2008)

Synthesis and Anticancer Evaluation of New Indole-Based Tyrphostin Derivatives and Their (p-Cymene)dichloridoruthenium(II) Complexes
por: Oberhuber, Natalie, et al.
Publicado: (2023)

Combination of ruthenium(II)-arene complex [Ru(η(6)-p-cymene)Cl(2)(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity
por: Berndsen, Robert H., et al.
Publicado: (2017)

Fine-Tuning the Activation Mode of an 1,3-Indandione-Based Ruthenium(II)-Cymene Half-Sandwich Complex by Variation of Its Leaving Group
por: Mokesch, Stephan, et al.
Publicado: (2019)

Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes
por: Hanif, Muhammad, et al.
Publicado: (2013)

Synthesis and Characterization of New Ruthenium (II) Complexes of Stoichiometry [Ru(p-Cymene)Cl(2)L] and Their Cytotoxicity against HeLa-Type Cancer Cells
por: Fuster, Marta G., et al.
Publicado: (2022)

Mechanistic study on substitution reaction of a citrato(p-cymene)Ru(ii) complex with sulfur-containing amino acids
por: Aizawa, Sen-ichi, et al.
Publicado: (2019)

Anticancer Ruthenium Complexes with HDAC Isoform Selectivity
por: Cross, Jasmine M., et al.
Publicado: (2020)

Controversial Role of Transferrin in the Transport of Ruthenium Anticancer Drugs
por: Levina, Aviva, et al.
Publicado: (2022)

The Vasorelaxant Effect of p-Cymene in Rat Aorta Involves Potassium Channels
por: Silva, Martapolyana T. M., et al.
Publicado: (2015)

Update on Monoterpenes as Antimicrobial Agents: A Particular Focus on p-Cymene
por: Marchese, Anna, et al.
Publicado: (2017)

p-Cymene Promotes Its Catabolism through the p-Cymene and the p-Cumate Pathways, Activates a Stress Response and Reduces the Biofilm Formation in Burkholderia xenovorans LB400
por: Agulló, Loreine, et al.
Publicado: (2017)

Ru(II)(ƞ(6)-p-cymene) Conjugates Loaded onto Graphene Oxide: An Effective pH-Responsive Anticancer Drug Delivery System
por: Akhter, Suffora, et al.
Publicado: (2022)

Ruthenium Complexes as Anticancer Agents: A Brief History and Perspectives
por: Lee, Sang Yeul, et al.
Publicado: (2020)

Anticancer evaluation of new organometallic ruthenium(ii) flavone complexes
por: Khater, Mai, et al.
Publicado: (2022)

Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds
por: Kljun, Jakob, et al.
Publicado: (2023)

(η(6)-p-Cymene)(1,3-dimesityl-2,3-dihydro-1H-imidazol-2-ylidene)bis(pentafluorobenzoato-κO)ruthenium(II) dichloromethane disolvate
por: Dorst, Konstantin, et al.
Publicado: (2012)

Tetraethylammonium trichlorido(η(6)-p-cymene)ruthenate(II)
por: Wu, Fang-Hui, et al.
Publicado: (2009)

Precursor prioritization for p-cymene production through synergistic integration of biology and chemistry
por: Lin, Hsi-Hsin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k6858kmun43iroqjk72rjq6ld7